AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18089770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous doses of PC-SOD (40-160 mg)
Number of subjects: 0
Study 18089770 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of PC-SOD (80 mg for 7 days)
Number of subjects: 0
Study 18089770 — intervention group
Group type: COMPARATOR
Intervention: Single 80 mg dose of PC-SOD
Number of subjects: 0
Study 16513919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention (4 education classes and individual counseling sessions)
Number of subjects: 70
Study 16513919 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine outpatient services, maintain usual lifestyle)
Number of subjects: 70
Study 12735413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous midwifery care
Number of subjects: 51
Study 12735413 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 51
Study 11002872 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 32
Study 9186076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (n = 14)
Number of subjects: 27
Study 9186076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (n = 13)
Number of subjects: 27
Study 9186076 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (added after 6 weeks if BP goal not achieved)
Number of subjects: 27
Study 9186076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and Lisinopril (combined with furosemide)
Number of subjects: 27
Study 9186076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and Lisinopril (in blacks)
Number of subjects: 27
Study 9186076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and Lisinopril (in nonblacks)
Number of subjects: 27
Study 8262083 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 80
Study 8262083 — intervention group
Group type: COMPARATOR
Intervention: Control (no graduated compression stockings)
Number of subjects: 80
Study 3911700 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 51
Study 3911700 — intervention group
Group type: COMPARATOR
Intervention: Oxycone-papaverine 5+50 mg
Number of subjects: 51
Study 29762909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide, single doses of 25‐400 mg followed by 50‐800 mg/day for 10 doses.
Number of subjects: 36
Study 29762909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide, up to 28 titrated doses from 100‐800 mg/day (Cohort F).
Number of subjects: 36
Study 29762909 — intervention group
Group type: COMPARATOR
Intervention: Cohorts A, B, and C (doses of 25-400 mg and 50-800 mg/day).
Number of subjects: 36
Study 29762909 — intervention group
Group type: COMPARATOR
Intervention: Cohort F (safety analysis only).
Number of subjects: 36
Study 29171071 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based support plus standard care (n=83)
Number of subjects: 174
Study 29171071 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=91)
Number of subjects: 174
Study 27063319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60
Study 27063319 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at effect‐site concentration of 1.5 ng/mL
Number of subjects: 60
Study 27063319 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 24486089 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir plus peginterferon/ribavirin therapy
Number of subjects: 265
Study 22482335 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily for 8 weeks
Number of subjects: 55
Study 22482335 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 55
Study 20579335 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behaviour therapy (CBT) for anxiety disorders
Number of subjects: 3962
Study 20579335 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behaviour therapy (CBT) for depression
Number of subjects: 3962
Study 20579335 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behaviour therapy (CBT) for mixed anxiety and depression
Number of subjects: 3962
Study 20579335 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling for depression and mixed anxiety and depression
Number of subjects: 3962
Study 20579335 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST) for depression and mixed anxiety and depression
Number of subjects: 3962
Study 17270528 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 22
Study 17270528 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive drugs (control)
Number of subjects: 22
Study 12781273 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 41
Study 12781273 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 41
Study 10787112 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Number of subjects: 1918
Study 10787112 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 1918
Study 10787112 — intervention group
Group type: COMPARATOR
Intervention: Placebo at home
Number of subjects: 1918
Study 10787112 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in hospital
Number of subjects: 1918
Study 9109134 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily ceftriaxone plus amikacin
Number of subjects: 265
Study 9109134 — intervention group
Group type: COMPARATOR
Intervention: Three times daily ceftazidime plus amikacin
Number of subjects: 265
Study 8260292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 20
Study 8260292 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen
Number of subjects: 20
Study 3980055 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 3980055 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 0
Study 3980055 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 30183329 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (Method A)
Number of subjects: 83
Study 30183329 — intervention group
Group type: COMPARATOR
Intervention: Placebo auricular acupressure (Method B)
Number of subjects: 83
Study 28219102 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute antioxidant supplementation
Number of subjects: 19
Study 28219102 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 19
Study 28219102 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant supplementation
Number of subjects: 19
Study 24999252 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable hemodynamic monitor (IHM)
Number of subjects: 550
Study 24999252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing knowledge of hemodynamic data
Number of subjects: 550
Study 24124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control
Number of subjects: 6
Study 24124952 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) control
Number of subjects: 6
Study 24124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control in euglycemic range (CL-Eu)
Number of subjects: 6
Study 24124952 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control in hyperglycemic range (CL-Hyper)
Number of subjects: 6
Study 22048173 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6)
Number of subjects: 1106
Study 22048173 — intervention group
Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine (Gardasil® Merck & Co., Inc., Months 0, 2, 6)
Number of subjects: 1106
Study 19118466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with externalized ureteral catheter
Number of subjects: 46
Study 19118466 — intervention group
Group type: COMPARATOR
Intervention: Tubeless PCNL with Double-J placement
Number of subjects: 46
Study 17715457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision and touch
Number of subjects: 18
Study 17715457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision and no touch
Number of subjects: 18
Study 17715457 — intervention group
Group type: EXPERIMENTAL
Intervention: No vision and touch
Number of subjects: 18
Study 17715457 — intervention group
Group type: EXPERIMENTAL
Intervention: No vision and no touch
Number of subjects: 18
Study 17715457 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (CS)
Number of subjects: 18
Study 15090013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus intralesional meglumine antimoniate (MA)
Number of subjects: 400
Study 15090013 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 400
Study 15090013 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (MA)
Number of subjects: 400
Study 10915072 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) therapy
Number of subjects: 157
Study 10915072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 10915072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 157
Study 8960472 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted cardioverter-defibrillator
Number of subjects: 196
Study 8960472 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 196
Study 1388172 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment methods for lateral epicondylitis
Number of subjects: 0
Study 1388172 — intervention group
Group type: COMPARATOR
Intervention: Placebo effect of all treatments
Number of subjects: 0
Study 3894482 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 7
Study 3894482 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 7
Study 31272465 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT + CSWT
Number of subjects: 72
Study 31272465 — intervention group
Group type: COMPARATOR
Intervention: OMT + sham procedure
Number of subjects: 72
Study 29654420 — intervention group
Group type: COMPARATOR
Intervention: Surgical stripping
Number of subjects: 33
Study 29654420 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser setting 1 (4.5 W, 50 Hz, 100% water, 80% air, 60 μs, 800 μm Tip; MZ8)
Number of subjects: 33
Study 29654420 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser setting 2 (2.5 W, 50 Hz, 20% water, 40% air, 700 μs, 800 μm Tip; MZ8)
Number of subjects: 33
Study 27466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative faces with lesions
Number of subjects: 120
Study 27466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative faces with lesions
Number of subjects: 120
Study 27466981 — intervention group
Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 120
Study 27466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces with large peripheral lesions (LP)
Number of subjects: 120
Study 24293167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C (2 g before surgery and 500 mg twice daily for 5 days after surgery)
Number of subjects: 100
Study 24293167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin C)
Number of subjects: 100
Study 24293167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C
Number of subjects: 100
Study 24293167 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 23733308 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus mefloquine (250 mg for 3 days, then 250 mg weekly)
Number of subjects: 0
Study 23733308 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 23733308 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus mefloquine
Number of subjects: 0
Study 20886185 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (30 mg BID starting 12-24 hours postoperatively)
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 10 mg BID
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 20 mg BID
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 40 mg QD
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 40 mg BID
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 80 mg QD
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 80 mg BID
Number of subjects: 1038
Study 20886185 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 (all doses except 10 and 20 mg BID)
Number of subjects: 1038
Study 18634152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose iloprost (up to 2 ng/kg body weight per minute)
Number of subjects: 50
Study 18634152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iloprost (0.5 ng/kg body weight per minute)
Number of subjects: 50
Study 18634152 — intervention group
Group type: COMPARATOR
Intervention: Both high-dose and low-dose iloprost
Number of subjects: 50
Study 18634152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose iloprost
Number of subjects: 50
Study 18634152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iloprost
Number of subjects: 50
Study 16671423 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐ICH group
Number of subjects: 149
Study 16671423 — intervention group
Group type: COMPARATOR
Intervention: U‐ICH group
Number of subjects: 149
Study 14637388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour marker guided treatment (salvage treatment)
Number of subjects: 109
Study 14637388 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (after radiological confirmation of metastases)
Number of subjects: 109
Study 11359261 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage MS fixtures
Number of subjects: 29
Study 11359261 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage MS fixtures
Number of subjects: 29
Study 11359261 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage TPS fixtures
Number of subjects: 29
Study 11359261 — intervention group
Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 29
Study 8773865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (visual evaluation of thumb movements)
Number of subjects: 42
Study 8773865 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (no visual evaluation of thumb movements)
Number of subjects: 42
Study 8773865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 1370236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP)
Number of subjects: 20
Study 1370236 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 20
Study 31758850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (DU) 1.5 mg
Number of subjects: 1147
Study 31758850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (DU) 0.75 mg
Number of subjects: 1147
Study 31758850 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (GLIM) or Insulin Glargine (GLAR)
Number of subjects: 1147
Study 31758850 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (GLAR)
Number of subjects: 1147
Study 30565017 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium and Vitamin E co-supplementation (250 mg/day magnesium plus 400 mg/day vitamin E)
Number of subjects: 60
Study 30565017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28655596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat, higher carbohydrate diet (fat 20%, carbohydrate 66% energy)
Number of subjects: 307
Study 28655596 — intervention group
Group type: COMPARATOR
Intervention: Moderate fat, moderate carbohydrate diet (fat 30%, carbohydrate 56% energy)
Number of subjects: 307
Study 28655596 — intervention group
Group type: COMPARATOR
Intervention: Higher fat, lower carbohydrate diet (fat 40%, carbohydrate 46% energy)
Number of subjects: 307
Study 26374138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention protocol (sevoflurane‐remifentanil‐rocuronium‐ropivacaine)
Number of subjects: 352
Study 26374138 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (isoflurane‐sufentanil‐atracurium‐levobupivacaine)
Number of subjects: 352
Study 26374138 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IRT > 20 min (n=190)
Number of subjects: 352
Study 26374138 — intervention group
Group type: COMPARATOR
Intervention: Patients with IRT ≤ 20 min
Number of subjects: 352
Study 23414120 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin intravenous (EIV) group
Number of subjects: 100
Study 23414120 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin subcutaneous (ESC) group
Number of subjects: 100
Study 21719898 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt supplement (YOG; n = 15)
Number of subjects: 29
Study 21719898 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic sucrose beverage (CONT; n = 14)
Number of subjects: 29
Study 21719898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 21481244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management of bipolar disorder (non-interventional, longitudinal study)
Number of subjects: 3000
Study 17209212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements for cancer prevention
Number of subjects: 0
Study 17209212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional agents
Number of subjects: 0
Study 17209212 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term prospective cohort studies
Number of subjects: 0
Study 16281923 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir treatment
Number of subjects: 0
Study 16281923 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 16281923 — intervention group
Group type: EXPERIMENTAL
Intervention: High disease activity
Number of subjects: 0
Study 12049443 — intervention group
Group type: EXPERIMENTAL
Intervention: Child therapy
Number of subjects: 61
Study 12049443 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent/teacher training
Number of subjects: 61
Study 12049443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined child therapy and parent/teacher training
Number of subjects: 61
Study 9855591 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioids (meperidine)
Number of subjects: 318
Study 9855591 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 318
Study 9855591 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (compliant patients)
Number of subjects: 318
Study 9855591 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioids (compliant patients)
Number of subjects: 318
Study 7794572 — intervention group
Group type: EXPERIMENTAL
Intervention: Finapres (FIN)
Number of subjects: 15
Study 1976938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bai‐Lin Tea
Number of subjects: 352
Study 1976938 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit Pill
Number of subjects: 352
Study 1976938 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Vitality pill
Number of subjects: 352
Study 1976938 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement or dietary modification
Number of subjects: 352
Study 1976938 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial slimming clubs
Number of subjects: 352
Study 1976938 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 352
Study 24646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (mean dose of approximately 3 mg on a b.i.d. regimen)
Number of subjects: 60
Study 24646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31755140 — intervention group
Group type: EXPERIMENTAL
Intervention: R with HP
Number of subjects: 64
Study 31755140 — intervention group
Group type: COMPARATOR
Intervention: NR with HP
Number of subjects: 64
Study 31755140 — intervention group
Group type: EXPERIMENTAL
Intervention: R with PI
Number of subjects: 64
Study 31755140 — intervention group
Group type: COMPARATOR
Intervention: NR with PI
Number of subjects: 64
Study 31554389 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model Questionnaire for Breast Self-examination and Screening Mammogram
Number of subjects: 103
Study 28391283 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy drink (250 mL, 12 mg isoflavones)
Number of subjects: 44
Study 28391283 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated black tea (300 mL, 67 mg catechins)
Number of subjects: 44
Study 28391283 — intervention group
Group type: COMPARATOR
Intervention: Water (300 mL, control)
Number of subjects: 44
Study 25811794 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1800 mg once-daily
Number of subjects: 556
Study 23902431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynatine(®) HNS (500 mg keratin plus vitamins and minerals)
Number of subjects: 50
Study 23902431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 50
Study 21478243 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Curriculum (GC)
Number of subjects: 39
Study 21478243 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 39
Study 19046856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (IVIP)
Number of subjects: 100
Study 19046856 — intervention group
Group type: COMPARATOR
Intervention: Support Services
Number of subjects: 100
Study 16919107 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin drink
Number of subjects: 36
Study 16919107 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study 16919107 — intervention group
Group type: COMPARATOR
Intervention: Fasted
Number of subjects: 36
Study 15310577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports massage applied to one leg for 3 days
Number of subjects: 16
Study 15310577 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no massage)
Number of subjects: 16